EUVIMEDEUVIMED entdecken
Crossref

Hemostatic powder versus conventional treatments for malignancy-related upper gastrointestinal bleeding

J. H. Yoon, D. H. Jung, C. W. Huh, J. C. Park, S. K. Shin, S. K. Lee, Y. C. Lee

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S321

DOI: 10.1055/s-0044-1783476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von J. H. Yoon und 6 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Endoscopic hemostasis is considered as 1st-line treatment of malignancy related gastrointestinal (GI) bleeding. Despite advances in endoscopic treatments, malignancy related GI bleeding is hard to manage with high rates of treatment failure and rebleeding. Recently, hemostatic powder (HP) has been used to treat malignancy related GI bleeding. Its adhesive and cohesive property fascilitates coagulation cascade, and it can be easily sprayed to the large surface of tumor bleeding with non-contact application. However, there are few reports about the efficacy of HP for malignancy-related upper GI bleeding (UGIB). Therefore, we aimed to assess the efficacy of HP compared with conventional treatments in terms of initial hemostasis and rebleeding rates for malignancy-related UGIB.

Methods

We retrospectively analyzed data of total 213 patients with malignancy related UGIB from 2 centers between January 2017 and April 2023. Of these patients, 86 patients were treated with HP and 127 patients were treated with conventional hemostatic treatments such as mechanical clipping and thermocoagulation. We compared the initial hemostasis success rates, amount of blood transfusion (units of RBC to restore the baseline Hb level), early rebleeding (within 72 hours), delayed rebleeding (above 72 hours), length of hospitalization (days), and 30-day all-cause mortality between HP group and conventional hemostasis group. [ 1 ]

Results

Among the total 213 patients, 4 patients had bleeding from esophagus, 190 patients from stomach, and 19 patients from duodenum. The immediate hemostasis success rate was significantly higher in HP group compared with the conventional treatments group (97.7% vs 90.6%, p =0.039). However, there was no significant difference in terms of amount of blood transfusion (2.1±1.34% vs 2.1±1.95%, p =0.979), early rebleeding rate (12.8% vs 10.2%, p =0.562), delayed rebleeding rate (20.9% vs 15.0%, p =0.259), length of hospitalization (14.0±17.08% vs 11.9±12.62%, p =0.33), and 30-day all-cause mortality (12.8% vs 10.2%, p =0.562). No adverse events were reported from the application of HP. On multivariable analysis, rockall score (OR=1.403, 95% CI 1.043 – 1.886), hemoglobin level at bleeding (OR=0.753, 95% CI 0.620 – 0.915), and prior cancer treatment history (OR=2.4, 95% CI 1.268 – 4.540) were significantly independent risk factors of rebleeding.

Conclusions

Hemostatic powder may be considered as effective and safe method for the endoscopic management of acute malignancy-related UGIB. To establish the proper role of HP, large prospective studies are needed. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Yoon, J. H., Jung, D. H., Huh, C. W., Park, J. C., Shin, S. K., Lee, S. K., & Lee, Y. C. (2024). Hemostatic powder versus conventional treatments for malignancy-related upper gastrointestinal bleeding. Endoscopy, 56(S 02 S 02), S321. https://doi.org/10.1055/s-0044-1783476

Vancouver

Yoon JH, Jung DH, Huh CW, Park JC, Shin SK, Lee SK, et al. Hemostatic powder versus conventional treatments for malignancy-related upper gastrointestinal bleeding. Endoscopy. 2024;56(S 02 S 02):S321. doi:10.1055/s-0044-1783476

BibTeX
@article{Yoon2024,
  author = {Yoon, J. H. and Jung, D. H. and Huh, C. W. and Park, J. C. and Shin, S. K. and Lee, S. K. and Lee, Y. C.},
  title = {Hemostatic powder versus conventional treatments for malignancy-related upper gastrointestinal bleeding},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S321},
  doi = {10.1055/s-0044-1783476}
}
Kostenlos starten →